0.76%
7.26%
8.13%
27.88%
19.28%
19.28%
-22.90%
AI Spotlight on PSG
Company Description
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany.The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo.It also offers products for the treatment of chronic indications, including pain and other age-related ailments.
The company sells its products through pharmacies and wholesalers.It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France.The company was founded in 2012 and is based in Gräfelfing, Germany.
Market Data
| Last Price | 26.6 |
| Change Percentage | 0.76% |
| Open | 26.6 |
| Previous Close | 26.4 |
| Market Cap ( Millions) | 319 |
| Volume | 226 |
| Year High | 27.4 |
| Year Low | 19 |
| M A 50 | 25.07 |
| M A 200 | 23.03 |
Financial Ratios
| FCF Yield | 8.30% |
| Dividend Yield | 5.11% |
| ROE | 48.84% |
| Debt / Equity | 1.65% |
| Net Debt / EBIDTA | -96.96% |
| Price To Book | 8.63 |
| Price Earnings Ratio | 16.97 |
| Price To FCF | 12.05 |
| Price To sales | 2.8 |
| EV / EBITDA | 7.35 |
News
- Jan -24 - Premier Dividend Stocks To Consider In January 2025
- Jan -06 - Discover 3 Hidden Small Cap Gems with Promising Potential
- Dec -16 - Three Leading Dividend Stocks To Consider
- Dec -06 - PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest
- Nov -30 - PharmaSGP Holding Third Quarter 2024 Earnings: In Line With Expectations
- Nov -27 - Synopex And 2 Other Undiscovered Gems To Enhance Your Portfolio
- Nov -15 - 3 Reliable Dividend Stocks With At Least 3.6% Yield
- Oct -30 - Bayerische Motoren Werke And 2 Other German Dividend Stocks To Consider
- Oct -14 - Discover Bayerische Motoren Werke And 2 Other German Dividend Stocks
- Oct -08 - Südwestdeutsche Salzwerke And 2 Other Undiscovered German Gems To Consider
- Sep -27 - Top 3 German Dividend Stocks To Consider
- Sep -18 - Three Undiscovered German Gems with Strong Foundations
- Sep -17 - Borussia Dortmund GmbH Kommanditgesellschaft auf Aktien And 2 Other Undiscovered Gems with Solid Fundamentals
- Sep -13 - Discovering 3 Undiscovered Gems in Germany
- Aug -30 - 3 Undiscovered Gems in Germany with Strong Fundamentals
- Aug -03 - Calculating The Intrinsic Value Of PharmaSGP Holding SE (ETR:PSG)
- Jun -23 - Interested In PharmaSGP Holding's (ETR:PSG) Upcoming €1.36 Dividend? You Have Three Days Left
- Apr -13 - Should You Be Impressed By VEON Ltd.'s (NASDAQ:VEON) ROE?
- Mar -17 - Does APG|SGA (VTX:APGN) Deserve A Spot On Your Watchlist?
- Dec -03 - Should You Be Adding Compagnie Financière Tradition (VTX:CFT) To Your Watchlist Today?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Health Brands
Expected Growth : 6 %
What the company do ?
Health Brands from PharmaSGP Holding SE offers a range of consumer healthcare products, including vitamins, minerals, and supplements, for preventative and self-care needs.
Why we expect these perspectives ?
Health Brands from PharmaSGP Holding SE's 6% growth is driven by increasing demand for over-the-counter (OTC) medications, expansion into emerging markets, and strategic acquisitions. Additionally, the company's focus on digitalization, e-commerce, and product innovation are contributing to its growth. Furthermore, the rising trend of self-care and preventive healthcare is also boosting the demand for Health Brands' products.
Segment n°2 -> Beauty Brands
Expected Growth : 8 %
What the company do ?
Beauty Brands from PharmaSGP Holding SE offers a diverse portfolio of well-known beauty and personal care brands, including StadaSKIN, Imedeen, and others.
Why we expect these perspectives ?
PharmaSGP Holding SE's Beauty Brands segment growth is driven by increasing demand for natural and organic products, expansion into emerging markets, strategic acquisitions, and a strong online presence. Additionally, the segment benefits from a growing middle class, increasing consumer spending on beauty and personal care, and a focus on product innovation and diversification.
Pharmasgp Holding Se Products
| Product Range | What is it ? |
|---|---|
| Omeprazole | A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and ulcers. |
| Pantoprazole | A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. |
| Esomeprazole | A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and erosive esophagitis. |
| Lansoprazole | A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and duodenal ulcers. |
| Rabeprazole | A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and duodenal ulcers. |
| Dexlansoprazole | A proton pump inhibitor used to treat conditions such as gastroesophageal reflux disease (GERD) and erosive esophagitis. |
PharmaSGP Holding SE's Porter Forces
Threat Of Substitutes
The threat of substitutes for PharmaSGP Holding SE is moderate due to the presence of alternative treatments and therapies.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of PharmaSGP Holding SE's products and the lack of substitutes.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the presence of multiple suppliers and the company's ability to negotiate prices.
Threat Of New Entrants
The threat of new entrants is high due to the growing demand for pharmaceuticals and the increasing number of new market entrants.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of established competitors and the high stakes in the pharmaceutical industry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 64.91% |
| Debt Cost | 4.13% |
| Equity Weight | 35.09% |
| Equity Cost | 4.13% |
| WACC | 4.13% |
| Leverage | 184.95% |
PharmaSGP Holding SE : Quality Control
PharmaSGP Holding SE passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHN.MI | Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The … |
| INCR | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis … |
| PPGN.SW | PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, … |
| SECARE.ST | Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the … |
| RJF.MC | Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Reig Jofre
A-Score
1-Year Total Return ->
🥈
PharmaSGP Holding
A-Score
1-Year Total Return ->
🥉
Pharmanutra
A-Score
1-Year Total Return ->
4
PolyPeptide
A-Score
1-Year Total Return ->
5
Swedencare
A-Score
1-Year Total Return ->
6
